摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,5-Dihydro-2-(6-hydroxy-2-benzothiazolyl)-4-thiazolecarboxylic acid potassium salt | 115144-35-9

中文名称
——
中文别名
——
英文名称
4,5-Dihydro-2-(6-hydroxy-2-benzothiazolyl)-4-thiazolecarboxylic acid potassium salt
英文别名
potassium;2-(6-hydroxy-1,3-benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylate
4,5-Dihydro-2-(6-hydroxy-2-benzothiazolyl)-4-thiazolecarboxylic acid potassium salt化学式
CAS
115144-35-9
化学式
C11H7KN2O3S2
mdl
——
分子量
318.4
InChiKey
UMBKGTQQGYPQBE-UHFFFAOYSA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 溶解度:
    DMF:16.7(Max Conc. mg/mL);52.45(Max Conc. mM)DMSO:7.5(Max Conc. mg/mL);23.55(Max Conc. mM)Ethanol:0.25(Max Conc. mg/mL);0.79(Max Conc. mM)PBS (pH 7.2):10.0(Max Conc. mg/mL);0.31(Max Conc. mM)Water:32.0(Max Conc. mg/mL);100.5(Max Conc. mM)

计算性质

  • 辛醇/水分配系数(LogP):
    -1.68
  • 重原子数:
    19
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.18
  • 拓扑面积:
    139
  • 氢给体数:
    1
  • 氢受体数:
    7

安全信息

  • 海关编码:
    2934999090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

制备方法与用途

D-荧光素钾盐是荧光素酶的水溶性底物,存在于多种发光生物体中。在ATP和荧光素酶的催化作用下,D-荧光素钾被氧化,产生蓝绿色的光(560nm),当底物过量时,产生的光量子数与荧光素酶的浓度呈正相关。编码荧光素酶的Luc基因是植物、哺乳动物细胞的常用报告基因。由于没有背景干扰,因此可以很容易地检测出低至0.02 pg 水平的荧光素酶。

115144-35-9

D-荧光素钾盐是一类在生物体中发现的能引起生物发光的杂环化合物,如萤火虫。在ATP存在下,萤光素酶将其氧化脱羧后会发光。化学研究中可用于荧光素酶的基板。

D-Luciferin是萤火虫荧光素酶的底物。

D-luciferin is the natural substrate of the enzyme luciferase (Luc), that catalyzes the production of the typical yellowgreen light of fireflies.The present review covers the synthesis of D-luciferin and derivatives or analogues that are substrates or inhibitors of the luciferase from the American firefly Photinus pyralis , the enzyme more frequently used in techniques of in vitro and optical imaging.
D-Luciferin exhibits a decrease in the measured K m in PC3M-Luc cell lysates with a K m of 34 μM.

Bioluminescence imaging (BLI) using the firefly luciferase (Fluc) as a reporter gene and D-luciferin as a substrate is currently the most widely employed technique. The total signal intensity is plotted against the time after D-luciferin injection to generate a time-intensity curve. In addition to the peak signal, the signals at fixed time points (5, 10, 15, and 20 min) after D-luciferin injection are determined as alternatives to the peak signal. The signal in a given time-intensity curve is normalized for the peak signal in the curve to represent the pattern of temporal changes after D-luciferin injection.
Inject with 10 μL of D-luciferin (intraperitoneally or intravenously) stock solution per gram of body weight: normally ~200 μL for a 20 g mouse for a standard 150 mg/kg injection.
Thaw D-Luciferin (either Potassium or Sodium Salt) at room temperature and dissolve in dPBS (no calcium or magnesium) to a final concentration of 15 mg/mL. Pre-wet a 0.22 μm filter by drawing through 5-10 mL of sterile H 2 O and discard water. Sterilize the D-Luciferin solution through the prepared 0.22 μm syringe filter.

用途
活细胞、组织或生物体内luc标记基因和荧光素酶-融合基因体内/体外表达的成像分析; 2)广泛用于报告基因分析,免疫分析和ATP荧光卫生监测分析;

文献信息

  • Humanized anti-human-PD-1 antibody and its use in cancer treatment
    申请人:OSE IMMUNOTHERAPEUTICS
    公开号:US11352430B2
    公开(公告)日:2022-06-07
    Described herein are humanized anti-PD-1 antibodies, nucleic acids encoding such, and uses thereof in enhancing immune responses by activating T cells and treating diseases such as cancer and an infectious disease.
    本描述中提供了人源化抗PD-1抗体、编码此类的核酸及其在通过激活T细胞增强免疫反应以及治疗癌症和传染病等疾病中的应用。
  • HUMANIZED ANTI-HUMAN-PD-1 ANTIBODY
    申请人:OSE Immunotherapeutics
    公开号:EP3883966A1
    公开(公告)日:2021-09-29
  • [EN] HUMANIZED ANTI-HUMAN-PD-1 ANTIBODY<br/>[FR] ANTICORPS ANTI-PD-1 ANTI-HUMAIN HUMANISÉ
    申请人:OSE IMMUNOTHERAPEUTICS
    公开号:WO2020127366A1
    公开(公告)日:2020-06-25
    Described herein are humanized anti-PD-1 antibodies, nucleic acids encoding such, and uses thereof in enhancing immune responses by activating T cells and treating diseases such as cancer and an infectious disease.
  • [EN] BIFUNCTIONAL ANTI-PD1/IL-7 MOLECULES<br/>[FR] MOLÉCULES BIFONCTIONNELLES ANTI-PD1/IL-7
    申请人:[en]OSE IMMUNOTHERAPEUTICS
    公开号:WO2022129512A1
    公开(公告)日:2022-06-23
    The present invention relates to bifunctional molecules comprising an IL-7 variant and having a particular scaffold and their uses.
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,4R)-Boc-4-环己基-吡咯烷-2-羧酸 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-N,3,3-三甲基-N-(苯甲基)丁酰胺 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S)-2-氨基-3,3-二甲基-N-2-吡啶基丁酰胺 (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,5R,6R)-5-(1-乙基丙氧基)-7-氧杂双环[4.1.0]庚-3-烯-3-羧酸乙基酯 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素(1-6) 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸